Rifabutin (LM427) is a rifamycin derivative containing a spiropiperazine group with broad-spectrum antibacterial activity. Its mechanism of action is the same as that of rifampicin, which can form a stable combination with the β subunit of the DNA-dependent RNA polymerase of microorganisms, inhibit the activity of this enzyme, and thereby inhibit the synthesis of bacterial RNA. It has been approved in foreign countries for the prevention and treatment of HIV-infected patients with Mycobacterium avium-Mycobacterium intracellulare complex (MAC) widely disseminated infection, and also for the treatment of multidrug-resistant tuberculosis.
